Your first launch price is an input to every price that follows

External reference pricing is usually described as a fact of life in global pricing. It is more useful to treat it as a sequencing constraint, because that is what it actually is.

The mechanism

Most countries do not set medicine prices independently. They look at a defined basket of comparator countries and price against it. So the price agreed in market one becomes an input to market two, which becomes an input to market three. The Euripid guidance on external reference pricing sets out how widely the practice varies in method across systems that share the same name¹.

Three systems show how that variation works, and why it matters.

Switzerland. The Federal Office of Public Health compares the ex-factory price of the same medicine across a defined basket of European countries. That comparison sits alongside a therapeutic cross-comparison when the reimbursed price on the Specialties List is set. The comparison is made on ex-factory prices rather than net prices after confidential rebates².

Canada. The PMPRB compares the Canadian list price against list prices in the PMPRB11: Australia, Belgium, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden and the UK. PMPRB defines list price explicitly as the ex-factory price before rebates and discounts³.

Norway. The Norwegian Medical Products Agency is the useful exception to the ex-factory shorthand. It uses the actual market price, defined as the price paid by the largest share of each market, across a nine-country basket. The maximum pharmacy purchase price is set as the mean of the three lowest observed prices in that basket⁴.

Note what that rule does to a sequence. It is not referencing your price. It is referencing the three lowest prices in a nine-country basket. One low launch does not enter as one data point among nine. It can enter as one of the three that set the ceiling.

Where the error happens

The pattern is familiar. A company launches first wherever approval looks fastest. Usually a smaller market. Usually at a lower price. Reasonable on its own terms, since the pathway was shorter and revenue starts sooner.

Eighteen months later that number appears in a basket for a market many times the size. There is no mechanism to unwind it.

What makes this structurally hard is who makes the decision. Sequencing is usually driven by regulatory timelines, by people optimising for approval speed. The price consequence lands on market access, who join the conversation after the sequence is fixed.

The distinction that gets lost

None of these systems reference the payer effective net cost. Switzerland references ex-factory. Canada references a list price it defines as pre-rebate. Norway references observed market prices and converts the result into a regulated pharmacy purchase price.

Confidential rebates mean the observable reference price can sit well above what any payer actually pays. That gap is not a rounding error. It is the reason a price you consider commercially acceptable in one market can be structurally unacceptable in another that references it.

What to ask before the first submission

These are questions for whoever owns the launch sequence, which in most companies is regulatory affairs working from approval timelines rather than pricing consequence. Market access should be in the room before the sequence is fixed, not after.

Which countries reference us, and are we in more than one basket.

What exactly do they reference: ex-factory, list, or observed market price. The three are not interchangeable.

Does any referencing country use a lowest-of rule rather than an average, and would our first price land inside it.

What does our proposed first price do to markets we have not modelled yet.